Intrinsic Value of S&P & Nasdaq Contact Us

Alkermes plc ALKS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • IE • USD

SharesGrow Score
79/100
6/7 Pass
SharesGrow Intrinsic Value
$195.47
+477.1%
Analyst Price Target
$46.83
+38.3%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Alkermes plc (ALKS) trades at a trailing P/E of 23.8, forward P/E of 46.3. Trailing earnings yield is 4.19%, forward earnings yield 2.16%. PEG 0.73 (Peter Lynch undervalued ≤1.0). Graham Number is $19.10.

Criteria proven by this page:

  • VALUE (83/100, Pass) — P/E is below market average (23.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.73); analyst target implies upside (+38.3%); earnings yield beats bond yields (4.19%).
  • PEG Ratio 0.73 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 4.19% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
  • Analyst consensus target $46.83 (+38.3% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 79/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
79/100
SG Score
View full scorecard →
VALUE
83/100
Price-to-Earnings & upside
Proven by this page
FUTURE
64/100
Analyst consensus
→ Forecast
~
PAST
75/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
MOAT
74/100
→ Income
GROWTH
90/100
→ Income
INCOME
70/100
→ Income

Valuation Snapshot — ALKS

Valuation Multiples
P/E (TTM)23.8
Forward P/E46.3
PEG Ratio0.73
Forward PEG0.73
P/B Ratio3.17
P/S Ratio3.95
EV/EBITDA14.4
Per Share Data
EPS (TTM)$1.47
Forward EPS (Est.)$0.73
Book Value / Share$11.05
Revenue / Share$8.96
FCF / Share$2.92
Yields & Fair Value
Earnings Yield4.19%
Forward Earnings Yield2.16%
Dividend Yield0.00%
Graham Number$19.10
SharesGrow IV$195.47 (+477.1%)
Analyst Target$46.83 (+38.3%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -40.4 4.39 6.96 11.29 -
2017 -53.2 2.10 6.98 9.29 -
2018 -32.9 2.60 3.91 4.18 -
2019 -16.3 -0.42 2.95 2.74 -
2020 -28.6 0.65 2.97 3.05 -
2021 -77.7 1.36 3.36 3.19 -
2022 -27.0 -0.12 4.10 3.85 -
2023 13.0 -0.04 3.83 2.77 -
2024 13.0 3.47 3.25 3.05 -
2025 19.1 -0.56 2.53 3.12 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-1.38 $745.69M $-208.44M -28%
2017 $-1.03 $903.37M $-157.95M -17.5%
2018 $-0.90 $1.09B $-139.31M -12.7%
2019 $-1.25 $1.17B $-196.62M -16.8%
2020 $-0.70 $1.04B $-110.86M -10.7%
2021 $-0.30 $1.17B $-48.17M -4.1%
2022 $-0.97 $1.11B $-158.27M -14.2%
2023 $2.10 $1.66B $355.76M 21.4%
2024 $2.17 $1.56B $367.07M 23.6%
2025 $1.43 $1.48B $241.66M 16.4%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.48 $-2.02 – $0.62 $1.8B $1.77B – $1.83B 7
2027 $0.73 $0.60 – $0.89 $1.88B $1.85B – $1.91B 6
2028 $1.30 $-0.24 – $3.61 $2.06B $2.06B – $2.06B 10
2029 $2.18 $2.09 – $2.33 $2.27B $2.21B – $2.39B 4
2030 $3.17 $3.06 – $3.40 $2.51B $2.44B – $2.65B 4
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message